Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials

Sajesh K Veettil,1 Nattawat Teerawattanapong,2 Siew Mooi Ching,3,4 Kean Ghee Lim,5 Surasak Saokaew,6–9 Pochamana Phisalprapa,10 Nathorn Chaiyakunapruk1,8,11,12

1School of Pharmacy/School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia; 2Division of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand; 3Department of Family Medicine, Faculty of Medicine and Health Sciences, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, 4Clinical School, Department of Surgery, International Medical University, Seremban, Negeri Sembilan, 5Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, 6School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 7Centre of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; 8Unit of Excellence on Herbal Medicine, School of Pharmaceutical Sciences, University of Phayao, Thailand; 9Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10School of Pharmacy, University of Wisconsin, Madison, USA; 11Health and Well-being Cluster, Global Asia Platform in the 21st Century (GA21) Platform, Monash University Malaysia, Selangor, Malaysia

Correspondence: Nathorn Chaiyakunapruk
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia
Tel: +60 3 551 4413
Email: nathorn.chaiyakunapruk@monash.edu

This article was published in the following Dove Press journal:
OncoTargets and Therapy
23 May 2017
Number of times this article has been viewed

Background: Protective effects of several chemopreventive agents (CPAs) against colorectal adenomas have been well documented in randomized controlled trials (RCTs); however, there is uncertainty regarding which agents are the most effective.

Methods: We searched for RCTs published up until September 2016. Retrieved trials were evaluated using risk of bias. We performed both pairwise analysis and network meta-analysis (NMA) of RCTs to compare the effects of CPAs on the recurrence of colorectal adenomas (primary outcome). Using NMA, we ranked CPAs based on efficacy.

Results: We identified 20 eligible RCTs enrolling 12,625 participants with a history of colorectal cancer or adenomas who were randomly assigned to receive either a placebo or one of 12 interventions. NMA using all trials demonstrated that celecoxib 800 mg/day (relative risk [RR] 0.61, 95% confidence interval [CI] 0.45–0.83), celecoxib 400 mg/day (RR 0.70, 95% CI 0.55–0.87), low-dose aspirin (RR 0.75, 95% CI 0.59–0.96) and calcium (RR 0.81, 95% CI 0.69–0.96) were significantly associated with a reduction in the recurrence of any adenomas. NMA results were consistent with those from pairwise meta-analysis. The evidence indicated a high (celecoxib), moderate (low-dose aspirin) and low (calcium) Grading of Recommendations, Assessment, Development and Evaluation (GRADE) quality. NMA ranking showed that celecoxib 800 mg/day and celecoxib 400 mg/day were the best CPAs, followed by low-dose aspirin and calcium. Considering advanced adenoma recurrence, only celecoxib 800 mg/day and celecoxib 400 mg/day were demonstrated to have a protective effect (RR 0.37, 95% CI 0.27–0.52 vs RR 0.48, 95% CI 0.38–0.60, respectively).

Conclusion: The available evidence from NMA suggests that celecoxib is more effective in reducing the risk of recurrence of colorectal adenomas, followed by low-dose aspirin and calcium. Since cyclooxygenase-2 (COX-2) inhibitors (eg, celecoxib) are associated with important cardiovascular events and gastrointestinal harms, more attention is warranted toward CPAs with a favorable benefit-to-risk ratio, such as low-dose aspirin and calcium.

Keywords: colorectal adenomas, chemoprevention, systematic review, meta-analysis, network meta-analysis, randomized controlled trials

Introduction

Colorectal cancer (CRC) is among the most common forms of cancer in the world, with ~1.36 million new cases in 2012; it is the fourth leading cause of cancer death worldwide.1 The burden of CRC in terms of mortality, morbidity and costs is enormous for the community.2,3 Moreover, CRC-related mortality is increasing owing to the
late stage at which many cases present. Therefore, effort is required to find effective ways to prevent this condition.

It is widely accepted that adenomas/polyps are precursors of CRC via adenoma–carcinoma sequence. Hence, colorectal adenomas are considered as a reasonable surrogate end point for trials in this area, especially in subjects with a history of CRC or adenomas, for whom the incidence rates are known to be higher than those in the general population. Early detection and removal of pre-cancerous colorectal adenomas by screening, followed by appropriate therapy and continued surveillance, can decrease mortality. Although many screening interventions are available for the detection and removal of asymptomatic adenomas and finding the early stages of CRC, their uptake continues to be low. Moreover, even after the removal of adenomas, the recurrence rate is reasonably high. Acceptance of continual screening recommendations involves a large volume of health care resources; its attainment will also depend on a high adherence rate and consistent follow-up. Therefore, increased attention is being given to the possible use of chemopreventive agents (CPAs) as a complement to, or substitute for, screening.

In the light of cyclooxygenase-2 (COX-2) overexpression associated with CRC tissue, nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have been the most highly researched drugs in the prevention of recurrent colorectal adenomas. However, many other potential CPAs have been investigated, ranging from calcium with or without vitamin D to micronutrients, such as folic acid and antioxidants.

Despite evidence of the effectiveness of COX-2 inhibitors and of aspirin at any dose in preventing colorectal adenomas, these agents are associated with important cardiovascular events and gastrointestinal harms. Low-dose aspirin used for cardiovascular protection may provide an additional advantage, as the balance of benefits and risks seems to be more favorable. Recent randomized controlled trials (RCTs) have demonstrated the moderate beneficial effect of low-dose aspirin on the incidence of adenomas. Similarly, evidence from good quality RCTs suggests a possible protective effect of calcium supplementation on the recurrence of adenomas, without important adverse effects. However, evidence of the comparative advantage of low-dose aspirin and calcium with other potential CPAs on adenoma recurrence is necessary to justify the continuous growth of these agents in this era of stagnant screening acceptance, limited endoscopic capacity and rising health care expenditures.

Choosing the most effective CPA for the prevention of the recurrence of adenomas in subjects with a history of CRC or adenomas remains an important consideration; however, uncertainty remains in the data informing the best choice. Hence, we performed network meta-analysis (NMA) to compare the effects of competing CPAs on the recurrence of colorectal adenomas. The results of our analysis can provide readers with useful information to guide clinical decision-making in this field.

Methods
Study design
This study was conducted as a part of a systematic review and NMA of CPAs for CRC, which has been registered (registration number: CRD42015025849) with International Prospective Register of Systematic Reviews (PROSPERO) previously. A complete description of the parent study design and methods has been published elsewhere. The reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Search strategy and study selection
We identified relevant studies by a systematic search of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, CINAHL Plus, International Pharmaceutical Abstracts and ClinicalTrials.gov website from January 2008 to September 2016. We developed the search strategy in MEDLINE and modified it for other databases (Table S1). The search was restricted to studies published from 2008 onward because studies published up to 2007 could be identified from the published systematic reviews. To identify studies not captured by database search, we manually checked the reference lists of published systematic reviews and identified articles. In the present study, we considered all RCTs with a follow-up period or duration of treatment at least 1 year and concerned with demonstrating the efficacy of CPAs (low- or high-dose aspirin [80–325 mg/day] with or without folic acid, folic acid, non-aspirin NSAIDs, vitamin D, calcium with or without vitamin D and any antioxidants) compared to placebo for the prevention of colorectal adenomas. We considered studies for inclusion if participants had a history of CRC or adenomas. Our primary outcome measure was the incidence of any recurrent adenomas. In subgroup analysis, the recurrence of advanced adenomas was considered separately.

Data extraction and quality assessment
Requisite data were extracted independently and in duplicate by two reviewers into a data extraction form (SKV and SMC). If multiple publications of the same trial were retrieved, only the most recent and informative publication was included.
Two reviewers (SKV and SMC) independently assessed the risk of bias (ROB) within each study by using a Cochrane ROB instrument.\textsuperscript{61,62} We evaluated sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other sources of bias. Reviewers resolved disagreements by discussion, and one of two arbitrators adjudicated any unsolved disagreements. When ROB varied across included studies, we stratified studies according to ROB and produced two estimates of the intervention effect: from trials at low ROB and from all studies.

**Evidence grading**

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach\textsuperscript{63,64} adapted to NMA\textsuperscript{65} was used to rate the quality of evidence of estimates (high, moderate, low and very low).

**Statistical analysis**

For direct comparison, a standard pairwise meta-analysis was conducted by using a random-effects model. If a direct comparison was based on two or more studies, heterogeneity between trials was assessed by considering the $I^2$ statistics.\textsuperscript{62} An $I^2$ estimate ≥50% was interpreted as evidence of substantial levels of heterogeneity.\textsuperscript{62} The outcome measure was estimated in relative risk (RR), which is the ratio between the incidences of colorectal adenoma in the intervention arm and those in the control arm along with a 95% confidence interval (CI).

A random-effects NMA was carried out by combining direct and indirect evidences.\textsuperscript{66} A model with either consistency or inconsistency was assessed in Stata version 14.0 (StataCorp, College Station, TX, USA) by contrasting direct and indirect estimates in each triangular loop using the methods described by Veroniki et al.\textsuperscript{67} Network inconsistency assumption, which refers to a disagreement between the direct and indirect estimates, was evaluated using the loop-specific approach described by Bucher et al.\textsuperscript{68} We also used the design-by-treatment interaction approach and node-splitting technique to assess the network inconsistency.\textsuperscript{66} The design-by-treatment interaction approach was used to assess inconsistency globally, while the Bucher et al\textsuperscript{68} method and node-splitting technique\textsuperscript{67} were used to assess inconsistency locally in all closed loops. To rank the intervention hierarchy in NMA, the rankograms, the surface area under the cumulative ranking (SUCRA) curves as proposed by Salanti et al\textsuperscript{69} and the mean ranks were estimated. The number-needed-to-treat was calculated in order to provide readers with information on the absolute effect of treatment on patients’ outcome.

Excluding treatments in NMAs can occasionally have the largest potential to change the results and reduce the applicability and usefulness of NMA.\textsuperscript{70} However, excluding treatment that is unimportant from a clinical point of view is justifiable.\textsuperscript{70} Although COX-2 inhibitors seem to be more effective in preventing recurrence of adenomas, the balance of benefits to risk does not favor chemoprevention.\textsuperscript{40} Hence, we performed the sensitivity analyses separately for low-bias risk trials and all trials (low- and high-bias risk trials) concerning the efficacy of CPAs, excluding COX-2 inhibitors, to establish the best evidence for potential interventions other than COX-2 inhibitors for adenoma prevention. Publication bias was examined with a comparison-adjusted funnel plot.

**Results**

**Search findings**

A flow diagram depicting the search and selection process is provided in Figure S1. Overall, 3,985 records were identified by searching databases and additional records. Ultimately, we identified 20 potentially eligible RCTs for inclusion in our analysis.\textsuperscript{10,16–21,26–36,71,72} Another 14 relevant articles were identified for CPAs but did not meet the eligibility criteria and were excluded with reasons (Table S2).\textsuperscript{14,15,22–25,73–80}

**Characteristics of the included studies**

All included studies were randomized and specific for the prevention of recurrent colorectal adenomas. Descriptions of included studies, interventions and outcomes are summarized in Tables S3–S5. A total of 12,625 participants who completed the follow-up colonoscopy and reported any adenoma recurrence were included in the main analysis. All trials included both men and women with a history of adenomas, except in the two-group randomization of the Baron et al\textsuperscript{28} 2015 study, where women were elected to be randomly assigned to receive either calcium or calcium plus vitamin D. The length of follow-up from recruitment to study was up to 2–3 years in ten trials and 4–5 years in six trials, whereas the follow-up of the remaining small trials ranged from ~1.5 to 15 years. Most of the CPA or combinations of CPA involved in comparison with placebo were any antioxidants (six trials), followed by calcium (five trials), high-dose aspirin (four trials), low-dose aspirin (three trials), folic acid (three trials), celecoxib 400 mg/day (two trials) and low-dose and high-dose aspirin plus folic acid (two trials); only one trial was available for the remaining interventions (celecoxib 800 mg/day, vitamin D, calcium plus vitamin D and aspirin plus calcium plus vitamin D). The dose ranges per day for
CPAs were as follows: calcium – 500–2,000 mg (elemental calcium), high-dose aspirin – 300–325 mg, low-dose aspirin – 80–160 mg and folic acid – 0.5–1 mg; celecoxib was used in doses of either 400 or 800 mg. All trials of antioxidants used comparisons of one or more antioxidants against placebo, and the doses were highly varied.

Quality of included studies
A summary of ROB of included RCTs and an ROB graph are presented in Table S6 and Figure S2. Among 20 RCTs, 13 had low ROB in most of the criteria and were categorized as RCTs with low ROB in our analysis.16–21,26,28,30,31,34,72,81 The remaining seven trials showed either unclear or high ROB according to most criteria.27,29,32,33,35,36,71 Because of differences in ROB, we carried out a sensitivity analysis by restricting to RCTs with low ROB.

Network consistency
The network of eligible comparisons for any adenoma incidence from all trials is shown in Figure 1. Graphical representations of all other networks are presented in Figures S3 and S4. An assessment of inconsistency is presented in detail in Tables S7–S9. The test of global inconsistency showed no significant difference between the consistency and inconsistency models (Table S7). Tests of local inconsistency using the loop-specific approach and the node-splitting model showed no significant differences between comparisons in both outcomes (Tables S8 and S9).

Efficacy of CPAs on any adenoma recurrence from pairwise meta-analysis
The results of any adenoma recurrence from single RCTs and standard pairwise meta-analysis of direct comparisons and their corresponding statistical heterogeneity are presented in full in Table S10. Out of 12 interventions, meta-analysis of efficacy was feasible for eight CPAs (any antioxidants, folic acid, calcium, celecoxib 400 mg/day and low- or high-dose aspirin with or without folic acid), for which at least two datasets were available. Among these eight CPAs, a random-effects meta-analysis of all trials showed that only celecoxib 400 mg/day (RR 0.70, 95% CI 0.64–0.76), low-dose aspirin (RR 0.83, 95% CI 0.70–0.99) and calcium (RR 0.83, 95% CI 0.75–0.93) were significantly associated with a reduction in recurrence of any adenomas compared to placebo. Restricting the analysis to trials with low bias risk demonstrated similar results.

In two factorial trials,16,30 comparison of low-dose aspirin versus high-dose aspirin showed that no interventions...
appeared to be superior in reducing adenomas (RR 0.67, 95% CI 0.37–1.21). However, in one RCT, low-dose aspirin plus folic acid demonstrated a significant association in reducing any adenomas compared to high-dose aspirin plus folic acid (RR 0.75, 95% CI 0.58–0.98), but not with placebo (RR 0.80, 95% CI 0.61–1.05). Another trial presented two sets of data for the comparison of calcium alone versus calcium plus vitamin D (factorial arm and two-arm data; provided by the author on request) and demonstrated no statistically significant association with the reduction in any adenomas (RR 0.98, 95% CI 0.86–1.12).

Finally, among the remaining CPAs (celecoxib 800 mg/day, vitamin D and calcium plus vitamin D) with only one RCT available, celecoxib 800 mg/day was statistically significantly associated with a reduction in the recurrence of any adenomas (RR 0.62, 95% CI 0.55–0.69) compared to placebo. In a recent RCT, the combination of low-dose aspirin, calcium and vitamin D was compared with placebo, but no statistically significant association was observed in the reduction of any adenomas (RR 0.94, 95% CI 0.68–1.29).

Efficacy of CPAs on adenoma recurrence from NMA

In order to compare and rank CPAs based on their effects on adenoma recurrence, we performed the NMA of the relevant RCTs. Network meta-analytic results on adenoma recurrence from all trials were reasonably comparable with those from standard pairwise meta-analysis (Figure 2). According to the findings from the NMA using all trials, celecoxib 800 mg/day (RR 0.61, 95% CI 0.45–0.83), celecoxib 400 mg/day (RR 0.70, 95% CI 0.55–0.87), low-dose aspirin (RR 0.75, 95% CI 0.59–0.96) and calcium (RR 0.81, 95% CI 0.68–0.97) were statistically significantly associated with the reduction in any recurrent adenomas. The number needed to treat (NNT) was 6, 8, 10 and 13 for celecoxib 800 mg/day, celecoxib 400 mg/day, low-dose aspirin and calcium, respectively. Since we observed varying adenoma recurrence rates in different RCTs, these values do not necessarily reflect the magnitude of the RR associated with the corresponding agents.

The results of NMA (estimated RR and SUCRA rank) for CPAs on the incidence of adenomas from all trials are given in Table S11 and Figure S5. SUCRA curves for any adenoma incidence are presented in Figure S6.

Subgroup analyses: advanced adenoma recurrence

A meta-analysis of all trials using a random-effects model informing the efficacy on advanced adenomas demonstrated that celecoxib 800 mg/day (RR 0.37, 95% CI 0.26–0.51) and celecoxib 400 mg/day (RR 0.48, 95% CI 0.38–0.60) were statistically significantly associated with a reduction in the recurrence of advanced adenomas compared to placebo; however, low-dose aspirin (RR 0.84, 95% CI 0.46–1.55) and calcium (RR 1.01, 95% CI 0.74–1.38) were not associated with reduced advanced adenoma risk. Restricting the analysis to trials with low bias risk demonstrated similar results. The results of pairwise meta-analyses on advanced adenoma are presented in Table S10.

Pairwise and NMA results for the incidence of advanced adenomas from all studies are presented in Figure 3. According to the NMA results on the advanced adenoma recurrence from all low-bias risk trials, only two CPAs (celecoxib 800 mg/day [RR 0.37, 95% CI 0.27–0.52] and celecoxib 400 mg/day [RR 0.48, 95% CI 0.38–0.60]) demonstrated evidence of efficacy in reducing advanced adenoma recurrence. Meanwhile, low-dose aspirin demonstrated only a moderately significant association in reducing advanced adenoma recurrence (RR 0.63, 95% CI 0.37–1.09). Results of NMA for CPAs on the incidence of advanced adenoma and the corresponding SUCRA curves are presented in Table S12 and Figures S7 and S8, respectively.

Sensitivity analyses

The results from multiple sensitivity analyses are reported in Tables S13 and S14 and Figures S9 and S10. Overall, the results were justifiably robust to the main analysis for each outcome based on excluding RCTs on celecoxib and restricting to RCTs with low ROB with or without celecoxib. The most important sensitivity analysis was the exclusion of seven RCTs, which exhibited either unclear or high ROB in most criteria. Restricting these RCTs did not have a marked effect on the results, although low-dose aspirin plus folic acid now showed a statistically significant reduction (RR 0.74, 95% CI 0.58–0.94) in adenoma recurrence compared to the main analysis (Table S13). Sensitivity analyses after excluding RCTs on celecoxib showed that low-dose aspirin with and without folic acid was ranked first and second, respectively, followed by calcium; however, no statistically significant association was demonstrated for both adenomas (Table S13) and advanced adenomas (Table S14).

GRADE summary of evidence

A summary of findings and strength of evidence from network meta-analyses for important CPAs demonstrating the evidence of efficacy in reducing adenoma recurrence is shown in Table S15. Using all included trials, our application...
<table>
<thead>
<tr>
<th>Treatment</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>NA</th>
<th>0.94 (0.68, 1.29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA + calcium + VitD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.02 (0.62, 1.66)</td>
</tr>
<tr>
<td>ASA-HD</td>
<td>1.49 (0.83, 2.70)</td>
<td>1.30 (0.99, 1.69)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.83 (0.68, 0.99)</td>
<td>NA</td>
<td>1.02 (0.61, 1.71)</td>
</tr>
<tr>
<td>ASA-HD + folic acid</td>
<td>1.18 (0.92, 1.52)</td>
<td>1.33 (1.02, 1.72)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.85 (0.70, 1.01)</td>
<td>NA</td>
<td>1.24 (0.75, 2.05)</td>
</tr>
<tr>
<td>ASA-LD</td>
<td>1.21 (0.89, 1.65)</td>
<td>1.14 (0.85, 1.49)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.76 (0.60, 0.96)</td>
<td>NA</td>
<td>1.32 (0.75, 2.31)</td>
</tr>
<tr>
<td>ASA-LD + folic acid</td>
<td>1.06 (0.73, 1.55)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.67 (0.52, 0.86)</td>
<td>NA</td>
<td>1.09 (0.67, 1.79)</td>
</tr>
<tr>
<td>Antiox</td>
<td>0.88 (0.64, 1.22)</td>
<td>0.83 (0.55, 1.25)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.77 (0.54, 1.11)</td>
<td>NA</td>
<td>1.15 (0.72, 1.86)</td>
</tr>
<tr>
<td>Calcium</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.98 (0.86, 1.12)</td>
<td>1.06 (0.80, 1.40)</td>
<td>0.99 (0.98, 1.10)</td>
<td>0.94 (0.74, 1.20)</td>
<td>0.94 (0.74, 1.20)</td>
<td>0.95 (0.82, 1.10)</td>
<td>1.34 (0.82, 2.21)</td>
<td></td>
</tr>
<tr>
<td>Calcium + VitD</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.97 (0.83, 1.14)</td>
<td>NA</td>
<td>1.09 (0.65, 1.82)</td>
</tr>
<tr>
<td>Cele-400</td>
<td>1.24 (0.87, 1.75)</td>
<td>1.29 (0.89, 1.69)</td>
<td>1.23 (0.89, 1.69)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.95 (0.82, 1.01)</td>
<td>NA</td>
<td>1.53 (0.90, 2.62)</td>
<td></td>
</tr>
<tr>
<td>Cele-800</td>
<td>1.41 (0.94, 2.11)</td>
<td>1.14 (0.84, 1.55)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.62 (0.55, 0.69)</td>
<td>NA</td>
<td>0.89 (0.54, 1.46)</td>
<td></td>
</tr>
<tr>
<td>Folic acid</td>
<td>0.82 (0.58, 1.15)</td>
<td>0.77 (0.58, 1.02)</td>
<td>0.91 (0.82, 1.01)</td>
<td>0.66 (0.48, 0.91)</td>
<td>0.58 (0.40, 0.85)</td>
<td>NA</td>
<td>1.06 (0.87, 1.28)</td>
<td>0.90 (0.70, 1.14)</td>
<td>0.95 (0.53, 1.31)</td>
<td>0.87 (0.44, 1.04)</td>
<td>1.16 (0.80, 1.69)</td>
<td>1.04 (0.61, 1.77)</td>
</tr>
<tr>
<td>Folic acid</td>
<td>0.82 (0.58, 1.15)</td>
<td>0.77 (0.58, 1.02)</td>
<td>0.91 (0.82, 1.01)</td>
<td>0.66 (0.48, 0.91)</td>
<td>0.58 (0.40, 0.85)</td>
<td>NA</td>
<td>1.06 (0.87, 1.28)</td>
<td>0.90 (0.70, 1.14)</td>
<td>0.95 (0.53, 1.31)</td>
<td>0.87 (0.44, 1.04)</td>
<td>1.16 (0.80, 1.69)</td>
<td>1.04 (0.61, 1.77)</td>
</tr>
<tr>
<td>PCB</td>
<td>0.94 (0.60, 1.45)</td>
<td>0.92 (0.75, 1.13)</td>
<td>0.91 (0.70, 1.19)</td>
<td>0.75 (0.67, 0.96)</td>
<td>0.70 (0.55, 0.87)</td>
<td>0.61 (0.45, 0.83)</td>
<td>1.05 (0.84, 1.31)</td>
<td>0.90 (0.67, 1.22)</td>
<td>0.90 (0.67, 1.22)</td>
<td>0.90 (0.67, 1.22)</td>
<td>0.90 (0.67, 1.22)</td>
<td>0.90 (0.67, 1.22)</td>
</tr>
</tbody>
</table>

**Figure 2** Pairwise (upper right portion) and network (lower left portion) meta-analytic results for incidence of any adenomas (all studies).

**Notes:** Outcomes are expressed as risk ratios (95% CIs). For the pairwise meta-analyses, RR < 1 indicates that the treatment specified in the row is more efficacious. For the NMA, RR < 1 indicates that the treatment specified in the column is more efficacious. Bold shaded results indicate statistical significance.

**Abbreviations:** Antiox, antioxidants; ASA-HD, high-dose aspirin; ASA-LD, low-dose aspirin; Calcium, calcium supplements; Cele-400, celecoxib 400 mg/day; Cele-800, celecoxib 800 mg/day; CI, confidence interval; NA, not applicable; NMA, network meta-analysis; PCB, placebo; RR, relative risk; VitD, vitamin D.
<table>
<thead>
<tr>
<th>Treatment</th>
<th>RR</th>
<th>95% CI</th>
<th>RR</th>
<th>95% CI</th>
<th>RR</th>
<th>95% CI</th>
<th>RR</th>
<th>95% CI</th>
<th>RR</th>
<th>95% CI</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA-HD</td>
<td>1.08</td>
<td>(0.70, 1.64)</td>
<td>1.39</td>
<td>(0.61, 3.12)</td>
<td>1.72</td>
<td>(0.85, 3.57)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>(0.68, 0.99)</td>
</tr>
<tr>
<td>ASA-HD + folic acid</td>
<td>1.92</td>
<td>(0.92, 4.00)</td>
<td>1.75</td>
<td>(0.86, 3.57)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>(0.64, 0.93)</td>
<td>NA</td>
<td>(0.87, 0.92)</td>
</tr>
<tr>
<td>ASA-LD</td>
<td>1.33</td>
<td>(0.76, 2.32)</td>
<td>1.27</td>
<td>(0.71, 2.30)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>(0.37, 0.75)</td>
<td>NA</td>
<td>(0.84, 0.55)</td>
</tr>
<tr>
<td>ASA-LD + folic acid</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>(0.41, 0.79)</td>
<td>NA</td>
<td>(0.76, 0.62)</td>
</tr>
<tr>
<td>Antiox</td>
<td>NA</td>
<td>NA</td>
<td>1.05</td>
<td>(0.42, 2.60)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>(0.45, 0.12)</td>
</tr>
<tr>
<td>Calcium</td>
<td>0.84</td>
<td>(0.54, 1.31)</td>
<td>0.81</td>
<td>(0.51, 1.30)</td>
<td>0.64</td>
<td>(0.35, 1.17)</td>
<td>0.54</td>
<td>(0.27, 1.08)</td>
<td>0.51</td>
<td>(0.26, 1.03)</td>
<td>NA</td>
<td>(1.04, 0.70)</td>
</tr>
<tr>
<td>Calcium + VitD</td>
<td>0.88</td>
<td>(0.53, 1.46)</td>
<td>0.85</td>
<td>(0.50, 1.44)</td>
<td>0.67</td>
<td>(0.35, 1.28)</td>
<td>0.56</td>
<td>(0.27, 1.18)</td>
<td>0.54</td>
<td>(0.26, 1.12)</td>
<td>1.04</td>
<td>(0.75, 1.45)</td>
</tr>
<tr>
<td>Cele-400</td>
<td>1.77</td>
<td>(1.16, 2.68)</td>
<td>1.70</td>
<td>(1.08, 2.67)</td>
<td>1.33</td>
<td>(0.74, 2.41)</td>
<td>1.13</td>
<td>(0.57, 2.24)</td>
<td>1.07</td>
<td>(0.54, 2.13)</td>
<td>2.09</td>
<td>(1.47, 2.99)</td>
</tr>
<tr>
<td>Cele-800</td>
<td>2.26</td>
<td>(1.40, 3.65)</td>
<td>2.17</td>
<td>(1.30, 3.61)</td>
<td>1.70</td>
<td>(0.90, 3.22)</td>
<td>1.44</td>
<td>(0.70, 2.97)</td>
<td>1.37</td>
<td>(0.67, 2.83)</td>
<td>2.68</td>
<td>(1.75, 4.10)</td>
</tr>
<tr>
<td>Folic acid</td>
<td>0.69</td>
<td>(0.49, 0.98)</td>
<td>0.66</td>
<td>(0.46, 0.96)</td>
<td>0.52</td>
<td>(0.30, 0.90)</td>
<td>0.44</td>
<td>(0.23, 0.83)</td>
<td>0.42</td>
<td>(0.21, 0.86)</td>
<td>0.82</td>
<td>(0.54, 1.23)</td>
</tr>
<tr>
<td>PCB</td>
<td>0.79</td>
<td>(0.47, 1.32)</td>
<td>0.76</td>
<td>(0.44, 1.31)</td>
<td>0.60</td>
<td>(0.31, 1.16)</td>
<td>0.50</td>
<td>(0.24, 1.07)</td>
<td>0.48</td>
<td>(0.23, 1.02)</td>
<td>0.94</td>
<td>(0.65, 1.35)</td>
</tr>
<tr>
<td>Celecoxib 400 mg/day</td>
<td>0.84</td>
<td>(0.59, 1.19)</td>
<td>0.81</td>
<td>(0.55, 1.19)</td>
<td>0.63</td>
<td>(0.37, 1.09)</td>
<td>0.54</td>
<td>(0.28, 1.02)</td>
<td>0.51</td>
<td>(0.27, 0.97)</td>
<td>0.99</td>
<td>(0.76, 1.30)</td>
</tr>
</tbody>
</table>

**Figure 3** Pairwise (upper right portion) and network (lower left portion) meta-analytic results for incidence of advanced adenomas (all studies).

**Notes:** Outcomes are expressed as risk ratios (95% CIs). For the pairwise meta-analyses, RR < 1 indicates that the treatment specified in the row is more efficacious. For the NMA, RR < 1 indicates that the treatment specified in the column is more efficacious. Bold shaded results indicate statistical significance.

**Abbreviations:** Antiox, antioxidants; ASA-HD, high-dose aspirin; ASA-LD, low-dose aspirin; Calcium, calcium supplements; Cele-400, celecoxib 400 mg/day; Cele-800, celecoxib 800 mg/day; CI, confidence interval; NA, not applicable; NMA, network meta-analysis; PCB, placebo; RR, relative risk; VitD, vitamin D.
of GRADE methodology that specifically adapted to NMA\(^5\) led us to conclude that the accumulated evidence for CPAs is as follows: celecoxib (high quality), low-dose aspirin (moderate quality) and calcium (low quality).

**Discussion**

To our knowledge, we performed the first NMA of CPAs in the prevention of recurrent colorectal adenomas as a part of our systematic review of CPAs for CRC prevention, which has been registered with PROSPERO previously.\(^5\) The currently available best evidence of adenoma prevention is based on the results of RCTs and standard meta-analyses of single CPAs or CPA classes. In the present systematic review, we captured evidence from 20 RCTs evaluating the role of 12 interventions (six CPAs with different doses and combinations) in >12,000 subjects with a history of CRC or adenomas, which makes the present review the largest ever analyzed in this field.

Pairwise meta-analytic results demonstrated that celecoxib 400 mg/day, low-dose aspirin and calcium were associated with a significant reduction in any adenomas. According to the evidence grading system using trials with low ROB, the level of evidence supporting the efficacy of these agents against any adenoma was high for celecoxib 400 mg/day, moderate for low-dose aspirin and low for calcium. The network meta-analytic results in terms of incidence of recurrent adenomas from all trials were justifiably comparable with those from standard pairwise meta-analysis. Using all trials and low-bias risk trials in NMA, we ranked five CPAs for which we found evidence of adenoma prevention (celecoxib 400 mg/day, celecoxib 400 mg/day, low-dose aspirin plus folic acid, low-dose aspirin and calcium). However, folic acid alone or in combination with aspirin (low- or high dose) did not show any significant effects on adenoma incidence in previous studies;\(^3\) this suggests that the effect of low-dose aspirin plus folic acid as shown by our NMA could be due to low-dose aspirin alone. Hence, we suggest that evidence of therapeutic activity in terms of efficacy for the secondary prevention of any adenoma recurrence was available for only four CPAs, in which celecoxib 400 mg/day and celecoxib 800 mg/day are the best candidates, followed by low-dose aspirin and calcium. The level of evidence supporting the efficacy of these CPAs using GRADE methodology adapted for NMA was high for celecoxib, moderate for low-dose aspirin and low for calcium.\(^6\)

COX-2 inhibitors (celecoxib 400–800 mg/day) had a greater protective effect than low-dose aspirin and calcium in reducing the incidence of any recurrent colorectal adenomas compared to placebo. However, the beneficial effect of COX-2 inhibitors as shown in RCTs did not persist during the posttreatment period,\(^20-22\) and an increased risk of adenoma incidence was observed \(\sim 1–2\) years after treatment cessation.\(^22,74\) Moreover, the risk of gastrointestinal\(^3\) and cardiovascular\(^8\) harms associated with these CPAs as shown in previous reviews does not appear to favor these drugs as CPAs.

To establish the best evidence for potential interventions other than COX-2 inhibitors for adenoma prevention, we excluded celecoxib and analyzed the data separately. A sensitivity analysis showed that low-dose aspirin (with or without folic acid) was ranked first, followed by calcium. Although calcium supplements modestly increase bone density\(^87\) and have a marginal efficacy against fracture,\(^88,89\) the risk of cardiovascular events, especially myocardial infarction,\(^90,91\) suggests that a reassessment of the role of calcium as a CPA is warranted. Meanwhile, high-quality evidence has shown that aspirin can decrease serious adverse events in patients at increased risk of cardiovascular disease.\(^92\) Although aspirin demonstrated a dose-dependent effect relating to the risks of gastrointestinal toxicity and hemorrhagic stroke,\(^41-43\) the use of low-dose aspirin in these individuals would result in positive cardiovascular effects and fewer adverse outcomes, and they would obtain the added benefit of fewer colorectal adenomas, as shown by our analysis. However, low-dose aspirin failed to show a significant benefit on advanced adenomas. Based on the existing good quality RCTs, only celecoxib demonstrated a protective effect against advanced adenomas in our NMA. The nonsignificant effect of low-dose aspirin on advanced adenoma could be due to the small information size (only 373 patients) and inconsistent low control event rate (1.2%–8.5%) in the three conducted trials used for our analysis.\(^16,17,30\) More high-quality RCTs comparing low-dose aspirin versus placebo are still needed to conclude the evidence for low-dose aspirin on both adenomas and advanced adenomas.

With regard to CPAs for which no evidence of adenoma prevention is available (antioxidants, folic acid, high-dose aspirin, low-dose aspirin plus calcium plus vitamin D and vitamin D alone), some considerations are needed. For any antioxidant and folic acid, the results from trials having a low ROB were consistent with the previous systematic
reviews, which demonstrated no evidence of reduction in any adenoma recurrence. For aspirin, there is no apparent explanation for the absence of a dose–response pattern, as seen in the case of celecoxib (400 mg/day and 800 mg/day), and the surprising lack of efficacy of the high-dose aspirin. A recent RCT demonstrated that the use of high-dose aspirin for 4 years increased the risk of adenomas, but not for 1 year; this observation suggests the need for a reassessment of preventive potential based on the duration of use. Although low-dose aspirin and calcium demonstrated a possible protective effect against adenomas, surprisingly, in one RCT, the combination of these agents (low-dose aspirin 75 mg plus elemental calcium 500 mg plus vitamin D) showed no significant effect. A possible explanation for this finding could be due to the use of lower doses of aspirin and calcium compared to previous studies (low-dose aspirin 81–160 mg; elemental calcium 1,200–2,000 mg) that showed a possible protective effect for these agents. Similarly, the lack of any effect of vitamin D observed in the present analysis was consistent with the given results from the recent RCT.

There are some limitations to this systematic review. There were few good quality RCTs, and the sample sizes of many interventional studies were small. We could not confirm the comparative advantage of all CPAs for which evidence of activity against adenomas is available over other interventions. Moreover, we could not demonstrate a protective effect against advanced adenomas for most CPAs due to insufficient information size from the trials. Furthermore, because the follow-up of studies was not sufficiently long, we could not explore the long-term effects of CPAs on the recurrence of adenomas and the progression to cancer.

**Conclusion**

The available evidence from NMA suggests that celecoxib is more effective in reducing the risk of recurrence of colorectal adenomas in patients with a previous history of CRC or adenomas, followed by low-dose aspirin and calcium. Since COX-2 inhibitors (eg, celecoxib) are associated with important cardiovascular events and gastrointestinal harms, more attention should be paid to CPAs with favorable benefit to risk ratio, such as low-dose aspirin and calcium. However, cardiovascular adverse effects associated with calcium supplementation in the light of new evidence and the deficiency of data informing the appropriate dose of aspirin (80 or 160 mg/day) in terms of efficacy and acceptability hamper recommendations concerning the use of these agents. More high-quality RCTs for low-dose aspirin and calcium are still needed in order to confirm their efficacy and acceptability in the secondary prevention of the recurrence of colorectal adenomas and advanced adenomas.

**Acknowledgments**
The authors wish to thank Prof Dato’ Dr (Mrs) Kew Siang Tong, School of Medicine, International Medical University, and Dr Muhammad Radzi bin Abu Hassan, Head of Gastroenterology Service, Ministry of Health, Malaysia, for their expertise and advice during the development of the protocol. The authors wish to thank Prof Brian L Furman, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK, for his valuable comments and support, which helped to improve the manuscript. The authors also wish to thank Mr Razman Shah MohdRazali, reference librarian, International Medical University, for providing the full-text articles whenever needed.

**Author contributions**

SKV drafted the protocol. NC revised the protocol. SKV and KGL coordinated the identification of trials. SKV and SMC conducted the trial selection and the data extraction. SKV and SMC independently assessed the ROB. NT and SKV conducted the standard statistical analyses, which were appraised by SS and NC. SKV and NT drafted the review. NT, KGL, SMC, SS, PP and NC revised the review. All authors participated in the interpretation of analyses, revised and commented on the article and approved the final version of the manuscript.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**


